News

Check back here regularly to find out what's going on at our company.

July 2020: Dr. Arnon Lavie of Enzyme by Design featured in Illinois Ventures Q2 2020 Roundup  

https://www.illinoisventures.com/news/coffee-with-a-founder-arnon-lavie-of-enzyme-by-design

July 2020: EbD cofounder Dr. Schalk named Scientist of the Month by the Association of Women in Science-Chicago.

http://www.awis-chicago.org/community/scientist-of-the-month/july-2020-sotm-dr-amanda-m-schalk

July 2020: EbD awarded SBIR Phase I supplemental grant to further strengthen their attack on hypersensitivity caused by asparaginases

October 2019: Two of our co-founders named as 40 Under 40 Chicago Scientists by Halo Cures

July 2019: EbD awarded SBIR Phase I grant to tackle hypersensitivity caused by asparaginases

June 2019: Enzyme by Design mentioned in Crain's Chicago Business

June 2019: UIC Today publishes news article about Enzyme by Design  

Photo by Jenny Fontaine - UIC

May 2019: University of Illinois at Chicago Cancer Center highlights Enyzme by Design's success at MedCity INVEST

Photo by Courtney Colvin, UI Cancer Center News

April 2019: Enzyme by Design wins the MedCity INVEST Biopharma Startup Contest

Chicago, Ill., April 25, 2019 – Yesterday afternoon, Enzyme by Design - a cancer therapeutic startup spun out from the University of Illinois at Chicago - was named the winner of the BioPharma category in the Pitch Perfect Startup contest at MedCity INVEST. This 2-day national conference focuses on healthcare investing in the Midwest and took place at the Ritz-Carlton at Water Tower place in downtown Chicago.  Enzyme by Design was one of 43 startups selected to give pitches at this event with technology ranging from therapeutics and diagnostics to medical devices and health IT.

Dr. Arnon Lavie, Enzyme by Design’s CEO, gave an engaging winning pitch on the exciting new cancer therapeutic his team engineered and are currently developing. His passion and commitment to the mission of designing safer oncology treatment options was readily apparent and permeated the room. Through precise enzyme engineering, his team’s biologic drug can selectively starve certain tumor cells of a key nutrient and kill them off without also causing debilitating side effects that plague current FDA-approved variants. Enzyme by Design is excited about finding the right investors who believe in the impact of our mission to develop safe and effective cancer therapeutics. The company is seeking seed funding to complete IND-enabling studies, which will allow for first-in-human trials that will establish its superior safety profile in a Phase I clinical trial.

Credit: MedCity News

https://medcitynews.com/2019/04/here-are-the-winners-from-2019s-medcity-invest-pitch-perfect-contest/

Jan 2019: EbD awarded NIH I-corp grant to interview 100 experts and develop a commercialization strategy      

Dec 2018: EbD awarded NSF I-corp grant through University of Chicago's Polsky Center for Entrepreneurshi and Education

Sept 2018: EbD awarded NIH STTR grant to develop a novel AML biologic drug      

Grant title: DEVELOPMENT OF A NOVEL SAFE AND EFFICACIOUS BIOLOGIC DRUG FOR THE TREATMENT OF AML

July 2018: EbD awarded NIH STTR grant to develop a novel L-asparaginase               

Grant title: A NOVEL GLUTAMINASE-FREE MAMMALIAN ASPARAGINASE WITH MINIMIZED IMMUNOGENICITY TO ENABLE EXPANDED USE IN CANCER THERAPY

Feb 2018: UIC Cancer Center publishes writeup on EbD's CEO               

UIC Cancer Center News: UIC Cancer Center publishes writeup on EbD's CEO 

Jan 2018: EbD publishes the advantage of low L-glutaminase L-asparaginase in Cancer Research

Nguyen et al Cancer Research 2018